TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $24.47 million. The enterprise value is $15.21 million.
| Market Cap | 24.47M |
| Enterprise Value | 15.21M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 67.78 million shares outstanding. The number of shares has increased by 19.44% in one year.
| Current Share Class | 63.50M |
| Shares Outstanding | 67.78M |
| Shares Change (YoY) | +19.44% |
| Shares Change (QoQ) | +12.78% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 64.04% |
| Float | 57.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.31 |
| Forward PS | 15.23 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of 1.32.
| Current Ratio | 3.37 |
| Quick Ratio | 3.23 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.50 |
Financial Efficiency
Return on equity (ROE) is -95.80% and return on invested capital (ROIC) is -34.20%.
| Return on Equity (ROE) | -95.80% |
| Return on Assets (ROA) | -31.53% |
| Return on Invested Capital (ROIC) | -34.20% |
| Return on Capital Employed (ROCE) | -84.38% |
| Weighted Average Cost of Capital (WACC) | 4.01% |
| Revenue Per Employee | $51,529 |
| Profits Per Employee | -$852,986 |
| Employee Count | 138 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.02% in the last 52 weeks. The beta is 1.07, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -79.02% |
| 50-Day Moving Average | 0.71 |
| 200-Day Moving Average | 0.97 |
| Relative Strength Index (RSI) | 27.60 |
| Average Volume (20 Days) | 1,134,737 |
Short Selling Information
The latest short interest is 1.75 million, so 2.58% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.60M |
| Short % of Shares Out | 2.58% |
| Short % of Float | 3.03% |
| Short Ratio (days to cover) | 5.61 |
Income Statement
In the last 12 months, TCRX had revenue of $7.11 million and -$117.71 million in losses. Loss per share was -$1.74.
| Revenue | 7.11M |
| Gross Profit | -88.32M |
| Operating Income | -118.54M |
| Pretax Income | -117.71M |
| Net Income | -117.71M |
| EBITDA | -115.66M |
| EBIT | -118.54M |
| Loss Per Share | -$1.74 |
Balance Sheet
The company has $100.16 million in cash and $90.89 million in debt, with a net cash position of $9.26 million or $0.14 per share.
| Cash & Cash Equivalents | 100.16M |
| Total Debt | 90.89M |
| Net Cash | 9.26M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 69.02M |
| Book Value Per Share | 1.02 |
| Working Capital | 73.44M |
Cash Flow
In the last 12 months, operating cash flow was -$116.28 million and capital expenditures -$2.16 million, giving a free cash flow of -$118.44 million.
| Operating Cash Flow | -116.28M |
| Capital Expenditures | -2.16M |
| Depreciation & Amortization | 2.88M |
| Net Borrowing | n/a |
| Free Cash Flow | -118.44M |
| FCF Per Share | -$1.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,667.02% |
| Pretax Margin | -1,655.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.44% |
| Shareholder Yield | -19.44% |
| Earnings Yield | -499.91% |
| FCF Yield | -503.00% |
Analyst Forecast
The average price target for TCRX is $2.67, which is 639.61% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.67 |
| Price Target Difference | 639.61% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 22.36% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -5.87 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.87 |
| Piotroski F-Score | 4 |